Aponeurotic Stimulation Effect on Parkinson Bradykinesia
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Parkinson Disease
- Sponsor
- Université Libre de Bruxelles
- Enrollment
- 11
- Locations
- 1
- Primary Endpoint
- 3D kinematic movement parameters and upper limb muscles electromyographic activation
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
Movement slowness (bradykinesia) is one of the main motor symptoms in Parkinson Disease (PD). Several studies have shown that patients with PD exhibit slowness because they are unable to modulate, in an optimal way, the velocity of voluntary motor acts not induced by external stimulation. Indeed, these patients have difficulties to integrate multi-sensorial information, mainly proprioception.
The investigators investigated changes in shoulder velocity during pointing movements by patients with PD after stimulation of soft tissues (aponeurosis) of upper limb muscles. The stimulation consisted of manipulating, with a hook (the diacutaneous fibrolysis method), the aponeurotic tissues enrobing the heads of the upper limb muscles. This technique has previously been shown to decrease passive tension and the tendon reflex response of the manipulated muscle group. The investigators hypothesis is that aponeurotic manipulation of shoulder muscles therefore creates a modification in the proprioceptive information, which in return temporarily decreases the bradykinesia of shoulder movements.
Investigators
Ana Bengoetxea
Assistant Professor
Université Libre de Bruxelles
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of Parkinson Disease
Exclusion Criteria
- •Patients with a limitation in the shoulder range of motion necessary to perform pointing movements
Outcomes
Primary Outcomes
3D kinematic movement parameters and upper limb muscles electromyographic activation
Time Frame: Participants will be followed for the duration of the clinical test (2 weeks)
Secondary Outcomes
- Unified Parkinson's Disease Rating Scale (UPDRS)(Participants will be followed for the duration of the clinical test (2 weeks))